Clinical trials
Schizophrenia clinical trials
Below are recruiting schizophrenia clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07557368Recruiting
Gamified games to help with thinking and recovery in schizophrenia
This study tests whether playing structured games on a phone or tablet can help people with schizophrenia improve their thinking skills, memory, and social confidence while in the hospital. The games are designed to be engaging and therapeutic.
ShanghaiAges 18–45 - NCT05184335RecruitingPhase 3
Brilaroxazine for adults with schizophrenia
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Phoenix, ArizonaAges 18–65 - NCT07521683Enrolling by invitationPhase 2
NS-136 treatment study for schizophrenia relapse
This study tests whether NS-136, a new medication, can help people with schizophrenia who are experiencing a relapse or worsening of symptoms. The study measures how well the medication works and what side effects it causes.
ShanghaiAges 18–65 - NCT07493551Recruiting
Bioequivalence study of a long-acting injection for schizophrenia
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
Beijing, Beijing MunicipalityAges 18–65 - NCT07484204RecruitingPhase 1
Study of a once-monthly injection for stable schizophrenia
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
AhmedabadAges 18–65 - NCT07467993RecruitingPhase 2
Testing GXV813 for hospitalized adults with schizophrenia
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Bentonville, ArkansasAges 18–65 - NCT07455929Recruiting
Yoga group therapy for schizophrenia
This trial tests whether a yoga-based group program can help people with schizophrenia spectrum disorders feel better. It's designed for outpatients who are stable enough to participate in group therapy.
BerlinAges 18–65 - NCT07428460Recruiting
Speedy brain stimulation for persistent negative symptoms in schizophrenia
This trial tests if a new, faster form of brain stimulation called accelerated neuromodulation therapy can help reduce negative symptoms (like loss of motivation or social withdrawal) in people with schizophrenia. It aims to see if this treatment can improve daily functioning and quality of life.
Montreal, QuebecAges 18–65 - NCT07434479Recruiting
Virtual reality mindfulness for aggression in schizophrenia
This study tests whether a virtual reality mindfulness program can help people with schizophrenia who have problems with impulsive aggression. You would use a VR headset for relaxation exercises and answer questions about your mood and behavior.
New York, New YorkAges 18–64 - NCT07419321Recruiting
Social isolation and aging in schizophrenia study
This study looks at how social isolation affects aging in people with schizophrenia. It may help researchers understand more about the health and well-being of older adults with this condition.
Hartford, ConnecticutAges 40–70 - NCT07423546RecruitingPhase 1/Phase 2
Brain scan study of Cobenfy in schizophrenia
This study tests a new medication called Cobenfy (also known as trospium) using brain scans to see how it affects dopamine in people with schizophrenia. If you have schizophrenia and are not currently on antipsychotics, you may be able to join.
New York, New YorkAges 18–50 - NCT05951660Recruiting
Study sexual side effects in schizophrenia with diabetes
This study looks at how sexual functioning is affected in people with schizophrenia, especially in those who also have diabetes or weight-related risk. It also examines how psychiatric medicines and diabetes/weight factors may be connected, which could help improve care for patients.
SlagelseAges 18 years+ - NCT07410507RecruitingPhase 2
Study of Brenipatide for adults with schizophrenia
This trial tests an investigational drug called brenipatide for people with schizophrenia who are already on a stable medication regimen. The goal is to see if adding this drug helps reduce relapses.
Little Rock, ArkansasAges 18–55 - NCT07404085Recruiting
Boosting thinking skills with training and medication in mood or schizophrenia disorders
This study tests whether adding a medication that may improve brain flexibility makes memory and thinking training work better for people with bipolar disorder, recurring depression, or schizophrenia spectrum disorders. It could help improve daily thinking skills and quality of life.
Frederiksberg, Capital Region of DenmarkAges 35–75 - NCT04959201RecruitingPhase 2
NMDA and antioxidant add-on to treat schizophrenia symptoms
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
TaichungAges 18–65 - NCT04917302RecruitingPhase 2
NMDA and anti-inflammatory add-on for treatment-resistant schizophrenia
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
TaichungAges 18–65 - NCT06021197RecruitingPhase 2
NMDA-enhancing treatment for cognitive symptoms in schizophrenia
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
TaichungAges 18–65 - NCT07363577RecruitingPhase 3
Testing LB-102 for adults with acute schizophrenia
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Bentonville, ArkansasAges 18–65 - NCT07344948RecruitingEarly Phase 1
Testing NTX-253 in healthy people and those with stable schizophrenia
This trial is testing a new medicine, NTX-253, to see how safe it is and how the body processes it. It is for healthy adults and adults with schizophrenia whose symptoms are stable on their current treatment.
Los Alamitos, CaliforniaAges 18–55 - NCT06872463Recruiting
Karolinska Schizophrenia Project: Brain study for first episode psychosis
This study examines the brain in people having their first episode of psychosis (like hearing voices or strong false beliefs) to understand more about schizophrenia and related conditions. It involves MRI scans and other tests over one year.
StockholmAges 18 years+ - NCT07309172Recruiting
KetoBrain: Brain Energy in Schizophrenia
This study looks at how your brain uses energy if you have early schizophrenia. You will have an MRI scan and possibly receive a special diet (ketogenic) to see if it helps your brain work better.
AarhusAges 18–35 - NCT04655235Recruiting
Study brain chemical systems in people with schizophrenia
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
Aachen, Northrine-WestphaliaAges 18–80 - NCT07290738Recruiting
TMS for negative symptoms in schizophrenia
This study tests whether a non-invasive brain stimulation technique called TMS can help reduce negative symptoms in people with schizophrenia. These symptoms include things like lack of motivation, limited speech, and not expressing emotions.
Houston, TexasAges 18–60 - NCT07288333RecruitingPhase 2
New medication for schizophrenia in hospitalized adults
This study tests an experimental medication (NBI-1117570) for adults with schizophrenia who are currently in the hospital because of a sudden worsening of symptoms. The goal is to see if this new treatment can help control symptoms better.
KazanlakAges 18–55
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for schizophrenia?
- Yes. Clin2 currently lists 306 recruiting schizophrenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a schizophrenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.